

### Publikationen 2003

Benkert O, Hippus H; Hrsg (2003) Unter Mitarbeit von Anghelescu I, **Gründer G**, **Hiemke C**, Lange-Asschenfeldt C, **Müller MJ**, **Szegedi A**, **Vernaleken I**. Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, 572 S.

**Dahmen N** (2003) Genetik komplexer neuropsychiatrischer Erkrankungen: eine Bestandsaufnahme. In: Hippus H (Hrsg) Universitätskolloquien zur Schizophrenie, Bd. 1. Steinkopff, Darmstadt. S. 229-232

**Dahmen N**, **Kasten M**, Wiczorek S, Gencik M, Eppelen JT, Ullrich B (2003) Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia 23: 14-19

**Dahmen N**, **Tonn P** (2003) Season of birth effect in narcolepsy. Neurology 61: 1016

Deutsche Hauptstelle für Suchtfragen (DHS) e.V. Hrsg (2003) Unter Mitarbeit von **Schmidt LG**, Konrad N, Rommelspacher H, Schmidt K, Singer MV, Teysen S. Alkoholabhängigkeit. Suchtmedizinische Reihe Bd. 1. DHS, Hamm, 132 S.

**Dragicevic A**, Fric M, Geiger E, Grasmäder K, **Härtter S**, Kuss H-J, Laux G, Lohmann PL, Mletzko W, **Müller MJ**, Rao ML, **Schanz B**, Scherer A, **Hiemke C** (2003) Therapeutisches Drug Monitoring von Antidepressiva. Psychoneuro 29: 40-43

**Fehr C**, Rademacher BL, Buck KJ (2003) Evaluation of the glutamate decarboxylase genes Gad1 and Gad2 as candidate genes for acute ethanol withdrawal severity in mice. Prog Neuropsychopharmacol Biol Psychiatry 27: 467-472

**Fellgiebel A**, **Scheurich A**, Siessmeier T, **Schmidt LG**, Bartenstein P (2003) Persistence of disturbed thalamic glucose metabolism in a case of Wernicke-Korsakoff syndrome. Psychiatry Res 124: 105-112

Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF, Goldman D, **Winterer G** (2003) Association of the G1947A COMT (Val<sup>108/158</sup>Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry 54: 40-48

Gallinat J, Senkowski D, Wernicke C, Juckel G, Becker I, Sander T, Smolka M, Hegerl U, Rommelspacher H, **Winterer G**, Herrmann WM (2003) Allelic variants of the functional promoter polymorphism of the human serotonin transporter gene is associated with auditory cortical stimulus processing. Neuropsychopharmacology 28: 530-532

Grasmäder K, Lohmann PL, Kuss HJ, Laux G, **Hiemke C**, Rao ML (2003) Therapeutisches Drug-Monitoring von Antidepressiva – therapeutischer und gesundheitsökonomischer Nutzen. MMP Medizinische Monatsschrift für Pharmazeuten 26: 162-164

**Grözinger M**, **Dragicevic A**, **Hiemke C**, **Shams M**, **Müller MJ**, **Härtter S** (2003) Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine. Pharmacopsychiatry 36: 3-6

**Gründer G** (2003) Schizophrenieforschung mit der Positronen-Emissions-Tomographie. In: Hippus H (Hrsg) Universitätskolloquien zur Schizophrenie, Bd. 1. Steinkopff, Darmstadt. S. 219-224

**Gründer G**, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60: 974-977

**Gründer G**, Siessmeier T, Piel M, **Vernaleken I**, Buchholz HG, Zhou Y, **Hiemke C**, Wong DF, Rösch F, Bartenstein P (2003) Quantification of D<sub>2</sub>-like dopamine receptors in the human brain with <sup>18</sup>F-desmethoxyfallypride. J Nucl Med 44: 109-116

**Gründer G**, **Vernaleken I**, **Müller MJ**, **Dauids E**, **Heydari N**, Buchholz HG, Bartenstein P, Munk OL, Stoeter P, Wong DF, Gjedde A, Cumming P (2003) Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology: 28: 787-794

**Gründer G**, Wong DF (2003) Die nächste Generation „atypischer“ Antipsychotika: Der Beitrag der Positronenemissionstomographie. Fortschr Neurol Psychiatr 71: 415-420

**Härtter** (2003) Therapeutisches Drug Monitoring (TDM) von Neuroleptika. In: Hippus H (Hrsg) Universitätskolloquien zur Schizophrenie, Bd. 1. Steinkopff, Darmstadt. S. 233-238

**Härtter S**, **Hiemke C** (2003) Therapeutisches Drug-Monitoring von neuen Antidepressiva und Antipsychotika. MMP Medizinische Monatsschrift für Pharmazeuten 26: 160-162

**Härtter S**, Hüwel S, Lohmann T, Abou El Ela A, Langguth P, **Hiemke C**, Galla HJ (2003) How does the benzamide antipsychotic amisulpride get into the brain?--An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology 28: 1916-1922

**Härtter S**, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K (2003) Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol 56: 679-682

**Hiemke C**, **Dragicevic A**, Fric M, Gaertner I, Grasmäder K, **Härtter S**, Hermann E, Kuss HJ, Laux, G, Oehl W, Rao ML, **Rollmann N**, **Weigmann H**, Weber-Labonte M, **Müller MJ** (2003) Therapeutisches Monitoring von trizyklischen Antidepressiva. PPT Psychopharmakotherapie 10: 11-14

**Hiemke C**, **Dragicevic A**, **Sachse J**, **Härtter S** (2003) Wechselwirkungen bei der Psychopharmakotherapie. AMT Arzneimitteltherapie 21: 331-335

**Hiemke C**, **Sachse J**, Köller J, Weigmann H, **Härtter S** (2003) HPLC with column-switching for therapeutic monitoring of psychoactive drugs. Clinical Laboratory 27: 26-27

**Hiemke C**, Weigmann H, **Härtter S** (2003) Interaktionen selektiver Serotonin-Wiederaufnahmehemmer mit Antipsychotika. In: König F, Kaschka WP (Hrsg). Interaktionen und Wirkmechanismen ausgewählter Psychopharmaka. Thieme, Stuttgart. S. 57-77

Himmerich H, **Szegedi A**, **Klawe C**, Anghelescu I, **Müller MJ** (2003) Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis. Eur Psychiatry 18: 318-319

Koksma J-J, Kesteren van RE, Rosahl TW, Zwart R, Smit AB, **Lüddens H**, Brussaard AB (2003) Oxytocin Regulates Neurosteroid Modulation of GABA<sub>A</sub> Receptors in Supraoptic Nucleus around Parturition. J Neurosci 23: 788-797

**Lange-Asschenfeldt C**, **Müller MJ**, **Szegedi A**, **Anghelescu I**, **Klawe C**, **Wetzel H** (2003) Symptom-Triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis. Eur Addict Res 9: 1-7

Lohmann PL, Frahnert C, Grasmäder K, **Hiemke C**, Laux G, Rao ML (2003) Klinische Relevanz des CYP2D6-Polymorphismus für die Therapie mit Antidepressiva und Neuroleptika. Psychopharmakotherapie 10: 35-38

**Mann K**, **Müller MJ**, **Hiemke C**, Benkert O (2003) Standardisierte Verlaufsdokumentation als Grundlage zur Verbesserung der Prozessqualität der stationären psychiatrischen Behandlung. Nervenarzt 74: 235-244

**Mann K**, **Pankok J**, **Connemann B**, **Röschke J** (2003) Temporal relationship between nocturnal erections and rapid eye movement episodes in healthy men. Neuropsychobiology 47: 109-114

Mulert C, Gallinat J, Dorn H, Herrmann WM, **Winterer G** (2003) The relationship between reaction time, error rate and anterior cingulate cortex activity. Int J Psychophysiol 47: 175-183

**Müller MJ** (2003) Psychopathologie und Psychopathometrie in der biologisch-psychiatrischen Schizophrenieforschung. In: Hippus H (Hrsg) Universitätskolloquien zur Schizophrenie, Bd. 1. Steinkopff, Darmstadt. S. 215-128

**Müller MJ**, **Dragicevic A** (2003) Standardized rater training for the Hamilton Depression Rating Scale (HAM-D-17) in psychiatric novices. J Affect Disord 77: 65-69

**Müller MJ**, **Dragicevic A**, Fric M, Gaertner I, Grasmäder K, **Härtter S**, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, **Rollmann N**, **Weigmann H**, Weber-Labonte M, **Hiemke C** (2003) Therapeutic Drug Monitoring of Tricyclic Antidepressants: How Does it Work under Clinical Conditions? Pharmacopsychiatry 36: 98-104.

**Müller MJ**, **Himmerich H**, **Kienzle B**, **Szegedi A** (2003) Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 77: 255-260

**Müller MJ, Sachse J, Vernaleken I, Gründer G, Härtter S, Hiemke C** (2003) Therapeutisches Drug-Monitoring von Amisulprid in der klinischen Routine. PPT Psychopharmakotherapie 10: 23-27

Mundle G, Banger M, Mugele B, Stetter F, Soyka M, Veltrup C, **Schmidt LG** (2003) AWMF-Behandlungsleitlinie: Akutbehandlung alkoholbezogener Störungen. Sucht 49: 147-167

Piel M, Schirmacher R, Höhnemann S, Hamkens W, Kohl B, Jansen M, **Schmitt U, Lüddens H**, Dannhardt G, Rösch F (2003) Synthesis and evaluation of 5,7-dichloro-4-(3-{4-[4-(2-[<sup>18</sup>F]fluoroethyl)-piperazin-1-yl]-phenyl}-ureido)-1,2,3,4-tetrahydroquinoline-2-carboxylic acid as a potential NMDA ligand to study glutamatergic neurotransmission in vivo. J Label Compd Radiopharm 46: 645-659

Rujescu D, Giegling I, Gietl A, Gonnermann C, Kirner A, Möller HJ, **Dahmen N** (2003) Association study of a SNP coding for a M129V substitution in the prion protein in schizophrenia. Schizophr Res 62: 289-291

**Sachse J, Härtter S, Müller MJ, Dragicevic A, Hiemke C** (2003) Therapeutisches Drug-Monitoring von Quetiapin. PPT Psychopharmakotherapie 10: 19-22

**Sachse J, Härtter S, Weigmann H, Hiemke C** (2003) Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. J Chromatogr B 784: 405-510

**Schanz B** (2003) DRGs und Psychiatrie. Psych Pflege 9: 281-286

**Schanz B** (2003) Kommunikation und Interaktion im diagnostischen Prozess. Psych Pflege 9: 130-133

**Schanz B** (2003) Labyrinth der Finanzierung. Heilberufe 55: 18-21

**Schmidt LG** (2003) Genießt Ihr Patient noch oder ist er schon Alkoholiker? MMW-Fortschritte der Medizin 145, Sonderheft 2: 31-36

**Schmidt LG**, Rommelspacher H (2003) Ergebnisse der klinischen Alkoholismusforschung. In: Hippus H (Hrsg) Universitätskolloquien zur Schizophrenie, Bd. 1. Steinkopff, Darmstadt. S. 113-115

**Schmidt LG**, Smolka MN, Rommelspacher H (2003) Dopaminergic Dysfunction – A common final pathway of addiction to alcohol, opiates and nicotine? In: Kuntze MF, Müller-Spahn F, Ladewig D, Bullinger AH (eds): Basic and Clinical Science of Opioid Addiction. Bibl Psychiatr. Basel, Karger, No 170, pp 39-45

Schumann G, Rujescu D, Kissling C, Soyka M, **Dahmen N**, Preuss UW, Wieman S, Depner M, Wellek S, Lascorz J, Bondy B, Giegling I, Angheliescu I, Cowen MS, Poustka A, Spanagel R, Mann K, Henn FA, **Szegedi A** (2003) Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts. Biol Psychiatry 54: 1422-1426

Schumann G, Rujescu D, **Szegedi A**, Singer P, Wiemann S, Wellek S, Giegling I, Klawe C, Anghelescu I, Heinz A, Spanagel R, Mann K, Henn FA, Dahmen N (2003) No association of alcohol dependence with a NMDA-receptor 2B gene variant. *Mol Psychiatry* 8: 11-12

Sinkkonen ST, Mansikkamäki S, Möykkynen T, **Lüddens H**, Uusi-Oukari M, Korpi ER (2003) Receptor subtype-dependent positive and negative modulation of GABA(A) receptor function by niflumic acid, a nonsteroidal anti-inflammatory drug. *Mol Pharmacol* 64: 753-763

Spiegel J, **Hansen C**, Baumgartner U, Hopf HC, Treede RD (2003) Sensitivity of laser-evoked potentials versus somatosensory evoked potentials in patients with multiple sclerosis. *Clin Neurophysiol* 114: 992-1002

**Szegedi A**, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003) Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. *J Clin Psychiatry* 64 : 413-420

**Szegedi A**, Müller MJ, Benkert O (2003) Psychopharmakotherapie. In: Gastpar MT, Kasper S, Linden M (Hrsg) *Psychiatrie und Psychotherapie*. Springer, Wien. S. 347-383

**Tadic A**, Rujescu D, **Szegedi A**, Giegling I, Singer P, Möller HJ, Dahmen N (2003) Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. *Am J Med Genet* 117B: 1-6

Wernicke C, Samochowiec J, **Schmidt LG**, Winterer G, Smolka M, Kucharska-Mazur J, Horodnicki J, Gallinat J, Rommelspacher H (2003) Polymorphisms in the N-methyl-D-aspartate receptor 1 and 2B subunits are associated with alcoholism-related traits. *Biol Psychiatry* 54: 922-928

Wieczorek S, Dahmen N, Jagiello P, Epplen JT, Gencik M (2003) Polymorphisms of the tumor necrosis factor receptors: no association with narcolepsy in German patients. *J Mol Med* 81: 87-90

Wieczorek S, Gencik M, Rujescu D, Tonn P, Giegling I, Epplen JT, Dahmen N (2003) TNFA promoter polymorphisms and narcolepsy. *Tissue Antigens* 61: 437-442.

**Winterer G** (2003) Valproate and GABAergic system effects (2003) *Neuropsychopharmacology* 28: 2050-2051

**Winterer G**, Coppola R, Egan MF, Goldberg TE, Weinberger DR (2003) Functional and effective frontotemporal connectivity and genetic risk for schizophrenia. *Biol Psychiatry* 54: 1181-1192

**Winterer G**, Egan MF, Raedler T, Sanchez C, Jones DW, Coppola R, Weinberger DR (2003) P300 and genetic risk for schizophrenia. *Arch Gen Psychiatry* 60: 1158-1167

**Winterer G**, Enoch M-A, White KV, Saylan M, Coppola R, Goldman D (2003) EEG phenotype in alcoholism: increased coherence in the depressive subtype. *Acta Psychiatr Scand* 108: 51-60

**Winterer G**, Goldman D (2003) Genetics of human prefrontal function. *Brain Res Rev* 43: 134-163

**Winterer G**, Mahlberg R, Smolka MN, Samochowiec J, Ziller M, Rommelspacher HP, Herrmann WM, **Schmidt LG**, Sander T (2003) Association analysis of exonic variants of the GABA<sub>B</sub>-receptor gene and alpha electroencephalogram voltage in normal subjects and alcohol-dependent patients. *Behav Genet* 33: 7-15

**Winterer G**, Smolka M, Samochowiec J, Ziller M, Mahlberg R, Gallinat J, Rommelspacher HP, Herrmann WM, Sander T (2003) Association of EEG coherence and an exonic GABA<sub>B</sub>R1 gene polymorphism. *Am J Med Genet.* 117B: 51-56

**Winterer G**, Weinberger DR (2003) Cortical signal-to-noise ratio: insight into the pathophysiology and genetics of schizophrenia. *Clin Neurosci Res* 3: 55-66